URL copied
India s indigenous vaccine COVAXIN has drawn global attention: ICMR
The Indian Council of Medical Research (ICMR) has said that Covaxin has drawn global attention. Covaxin is a COVID-19 vaccine being developed by ICMR-Bharat Biotech. It is now undergoing phase-3 trials.
The ICMR in a tweet said that India s indigenous vaccine has achieved remarkable feat. Data generated from within India underlines impressive safety and immunogenicity profile of Covaxin and sparks Lancet s interest in publishing them. Encouraging Phase I and Phase II COVAXIN trial results have paved the path for Phase III Clinical Trial in India, which is currently ongoing at 22 sites, the ICMR said.